InfuSystem Holdings, Inc. Reports Third Quarter Revenue of $16.6 Million and Net Profit of $0.04 Per Share
MADISON HEIGHTS, Mich.-- InfuSystem Holdings, Inc. (NYSE MKT:INFU) (“InfuSystem” or the “Company”), a leading national provider of infusion pumps and related services for the healthcare industry in the United States and Canada, today reported that net income in the third quarter was $0.9 million, equal to $0.04 per diluted share, compared to $0.6 million, or $0.03 per diluted share, in the prior year period. Net Income for the nine months ended September 30, 2014 was $2.3 million, or $0.10 per diluted share, compared to $0.8 million in net income and $0.04 per diluted share in the prior year period.
Revenues in the third quarter of 2014 were $16.6 million, up $0.9 million, or 6%, from $15.7 million in the third quarter of 2013. During the period, net revenues from rentals remained constant, while net revenues from product sales increased 69% over the same period in 2013. Revenue for the nine months ended September 30, 2014 was $50.2 million, an 11% increase over the same prior year period. During the period, net revenues from rentals increased 6% while net revenues from product sales increased 71% over the same period in 2013. The increase in revenues was primarily related to net additional rental and sales customers and increased penetration into existing rental and sales customer accounts, offset by a higher mix of Medicaid and patient payors in our rental business. These generally have lower net revenue rates than commercial payors. Such shifts have come, the Company believes, due to the Affordable Care Act.
“The successful implementation of our IT strategy transforms the way we do business and establishes new market opportunities for our services,” stated Eric K. Steen, Chief Executive Officer. “We continue to grow in all business areas: rentals, equipment sales and service, and sales of disposable products. We have also made significant investments in our pump fleet in the first nine months of the year of $3.7 million that positions us well for future growth.”
Commenting on a final rule related to competitive bid pricing issued on October 31, 2014 by the Centers of Medicare and Medicaid Services (“CMS”) and published in the Federal Register on November 6, 2014, Mr. Steen offered the following statement: “This definitive CMS ruling on non-competitive bid areas will have no impact on the Company's financials in 2015. We believe that our focus on improving our commercial contracts, along with operational and improvements in IT, could potentially offset some or all of these reductions in 2016 going forward.”
Gross profit for the three months ended September 30, 2014, was $11.7 million, a 3% increase compared to the same prior year period. For the nine months ended September 30, 2014, gross profit was $35.7 million, an increase of $3.6 million, or 11%, over the same prior year period.
Selling and marketing expenses were $2.5 million compared to $2.4 million for the three months ended September 30, 2013. Year-to-date selling and marketing expenses are up $0.5 million over the same prior year period, but as a percentage of total revenues such expenses are down from 16% to 15% for the same comparable periods, continuing our leverage on selling expenses. The increase in selling and marketing expenses was mainly attributed to increased commissions based on higher revenue for the comparable periods.
Mr. Steen emphasized that a number of recent accomplishments relate directly to building competitive advantage as well as creating shareholder value. “We now have 25 oncology infusion centers with full electronic medical records (“EMR”) connectivity. We now receive 40% of our orders electronically through our paperless iPad ordering system. Our Pump Web Portal helps our customers manage the care and life-cycle of their pumps far more efficiently. And our Block Pain Dashboard helps an increasing number of post-surgical pain-patients record information on Pain scores that can trend and be shared with clinicians to help future patients.”
Mr. Steen concluded, “The most encouraging aspect of our third quarter performance is the continued high patient-satisfaction scores we are earning and what this means to our future. In the Affordable Care Act (“ACA”) environment, patients will be at the top of the payment pyramid, and these scores will increasingly dictate actual payments.”
During the three months ended September 30, 2014, general and administrative (“G&A”) expenses were $4.9 million compared to $4.6 million for the same prior year period. The increase in G&A expense versus the same prior year period was mainly attributed to increases in spending on Information Technology and Pain Management initiatives of $0.2 million; charge-off of pumps of $0.1 million and increases in compensation and headcount of $0.5 million offset by savings of $0.4 million in professional fees. The Company has brought some professional services in-house previously performed by outside advisors, including tax, legal, information technology and internal audit. G&A expenses have increased slightly from 29% to 30% of revenues for the third quarter of 2014 compared to the same period in the prior year. For the nine months ended September 30, 2014, G&A has increased by $0.1 million compared to the same prior year period, mainly attributed to increases in spending on IT and Pain Management for $0.5 million; a write-off of pumps of $0.3 million, severance of $0.2 million and increases in compensation and benefits, including increased headcount, of $0.9 million offset by savings of $1.2 million in professional fees and $0.4 million in stock-based compensation.
Other expenses were consistent for the three months ended September 30, 2014 compared to the same prior year period. The change in the estimated useful life of our medical equipment, which occurred in the first quarter of this year, was accounted for as a change in accounting estimate, on a prospective basis, effective January 1, 2014. The change in estimated useful life resulted in $0.4 million less in depreciation expense for the quarter ended September 30, 2014 than otherwise would have been recorded. As a result, cost of revenues in the current period is $0.4 million less than the same prior year period and is $1.4 million less year-to-date compared to the prior year.
Adjusted EBITDA was $4.2 million for the third quarter of 2014 compared to $4.3 million in the same prior year period. For the nine months ended June 30, 2014, Adjusted EBITDA increased $0.2 million to $11.5 million compared to the same prior year period, despite the increased investments in IT and Pain Management, the write-off of pumps, and severance totaling $1.0 million. The Company utilizes Adjusted EBITDA as a means to measure its operating performance. A reconciliation from Adjusted EBITDA, a non-GAAP measure, to net income can be found in the appendix.
Financial Condition
Net cash provided by operations for the nine months ended September 30, 2014 was $4.2 million compared to cash generated of $4.8 million for the prior year period. The decrease in cash provided is primarily due to changes in accounts payable and other accruals.
As of September 30, 2014, we had cash and cash equivalents of $1.9 million and $3.6 million of availability under the Revolver compared to $1.1 million and $5.9 million, respectively, at December 31, 2013. Our availability in the future will be impacted, both negatively and positively at different times, as we deal with transitioning approximately 2,000 pumps that are nearing end of life in May 2015 with a certain manufacturer. The issue of transitioning from these pumps has accelerated due to the mix of lost facilities primarily using these pumps while we are placing new facilities on different pumps. To date, this has resulted in additional capital purchases of $1.4 million. Not all of these pumps will need to be replaced as we are focused on, and have already improved upon, increasing field utilization. As we take advantage of rebate programs offered by many manufacturers for this certain pump, additional purchases will occur, but at a discounted price. We do not believe that this transition will negatively impact our results of operations, as current rebates exceed the net book value of these pumps.
Total debt less cash on hand (“Net Debt”) as of September 30, 2014 was $26.0 million compared to last fiscal year of $25.6 million and prior year quarter of $26.7 million.
“With the challenges of the ACA on our payor mix, the transitioning of end of life pumps, the planned increases in IT and for Pain Management of $0.5 million – along with the unplanned charges of $0.5 million, we are extremely pleased with essentially maintaining year-to-date Adjusted EBITDA levels and strong liquidity,” said Jonathan P. Foster, Chief Financial Officer. “We continue to focus on recurring rental revenue with our investments in our pump fleet while our broker trader desk has successfully transitioned sales to occur over the year – versus an end of the year event. Lowering net debt balances, however, remains a priority, second to growth in our recurring rental revenue,” he concluded.
Guidance
The Company maintained 2014 Guidance of high single digit revenue growth and said it expects this rate to continue through 2015. It is important to note that the Company’s Form 10-Q for the quarter ended September 30, 2014, includes comments regarding the recent announcements by the Centers for Medicare and Medicaid Services (“CMS”).
Conference Call
The Company will conduct a conference call for investors on Monday, November 10, 2014 at 9:00 a.m. Eastern Standard Time to discuss third quarter performance and results. Eric K. Steen, Chief Executive Officer, Jan Skonieczny, Chief Operating Officer, and Jonathan P. Foster, Chief Financial Officer, will discuss the Company’s financial performance and answer questions from the financial community. To participate in this call, please dial in toll-free 800-447-0521 and use the confirmation number 38393591. The release will be available on most financial websites. Additionally, a Web replay will be available on the Company’s website for 30 days.
Non-GAAP Measures
This press release contains information prepared in conformity with GAAP as well as non-GAAP information. It is management’s intent to provide non-GAAP financial information in order to enhance readers’ understanding of its consolidated financial information as prepared in accordance with GAAP. This non-GAAP information should be considered by the reader in addition to, but not instead of, the financial statements prepared in accordance with GAAP. Each non-GAAP financial measure and the corresponding GAAP financial measure are presented so as to not imply that more emphasis should be placed on the non-GAAP measure. The non-GAAP financial information presented may be determined or calculated differently by other companies. Additional information about non-GAAP financial measures and a reconciliation of those measures to the most directly comparable GAAP measures are included later in this release.
About InfuSystem Holdings, Inc.
InfuSystem Holdings, Inc. is a leading provider of infusion pumps and related services to hospitals, oncology practices and other alternate site healthcare providers. Headquartered in Madison Heights, Michigan, the Company delivers local, field-based customer support and also operates Centers of Excellence in Michigan, Kansas, California, Texas and Ontario, Canada. The Company’s stock is traded on the NYSE MKT under the symbol INFU.
Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” “strategy,” “future,” “likely,” variations of such words, and other similar expressions, as they relate to the Company, are intended to identify forward-looking statements. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. In connection with the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, the Company is identifying certain factors that could cause actual results to differ, perhaps materially, from those indicated by these forward-looking statements. Those factors, risks and uncertainties include, but are not limited to, potential changes in overall healthcare reimbursement, including CMS competitive bidding, sequestration, concentration of customers, increased focus on early detection of cancer, competitive treatments, dependency on Medicare Supplier Number, availability of chemotherapy drugs, global financial conditions, changes and enforcement of state and federal laws, natural forces, competition, dependency on suppliers, risks in acquisitions & joint ventures, U.S. Healthcare Reform, relationships with healthcare professionals and organizations, technological changes related to infusion therapy, dependency on websites and intellectual property, the ability of the Company to successfully integrate acquired businesses, dependency on key personnel, dependency on banking relations and covenants, and other risks associated with our common stock, as well as any litigation to which the Company may be involved in from time to time; and other risk factors as discussed in the Company’s annual report on Form 10-K for the year ended December 31, 2013 and in other filings made by the Company from time to time with the Securities and Exchange Commission, including our Form 10-Q for the third quarter of 2014. Our Annual Report on Form 10-K is available on the SEC’s EDGAR website at www.sec.gov, and a copy may also be obtained by contacting the Company. All forward-looking statements made in this press release speak only as of the date of this report. We do not intend, and do not undertake any obligation, to update any forward-looking statements to reflect future events or circumstances after the date of such statements.
Additional information about InfuSystem Holdings, Inc. is available at www.infusystem.com.
|
INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES |
|||||||||||
|
CONDENSED CONSOLIDATED BALANCE SHEETS |
|||||||||||
| September 30, | December 31, | ||||||||||
|
(in thousands, except share data) |
2014 | 2013 | |||||||||
| (Unaudited) | |||||||||||
| ASSETS | |||||||||||
| Current Assets: | |||||||||||
| Cash and cash equivalents | $ | 1,902 | $ | 1,138 | |||||||
|
Accounts receivable, less allowance for doubtful accounts of $5,287 |
|||||||||||
|
and $4,774 at September 30, 2014 and December 31, 2013, respectively |
11,505 | 10,697 | |||||||||
| Inventory | 1,589 | 1,234 | |||||||||
| Other current assets | 621 | 518 | |||||||||
| Deferred income taxes | 2,296 | 2,296 | |||||||||
| Total Current Assets | 17,913 | 15,883 | |||||||||
| Medical equipment held for sale or rental | 2,365 | 3,664 | |||||||||
| Medical equipment in rental service, net of accumulated depreciation | 17,662 | 14,438 | |||||||||
| Property & equipment, net of accumulated depreciation | 2,370 | 872 | |||||||||
| Deferred debt issuance costs, net | 1,349 | 1,817 | |||||||||
| Intangible assets, net | 24,461 | 24,182 | |||||||||
| Deferred income taxes | 14,696 | 16,300 | |||||||||
| Other assets | 208 | 217 | |||||||||
| Total Assets | $ | 81,024 | $ | 77,373 | |||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||||||
| Current Liabilities: | |||||||||||
| Accounts payable | $ | 4,570 | $ | 4,736 | |||||||
| Current portion of long-term debt | 4,238 | 5,118 | |||||||||
| Other current liabilities | 3,303 | 3,187 | |||||||||
| Total Current Liabilities | 12,111 | 13,041 | |||||||||
| Long-term debt, net of current portion | 23,631 | 21,609 | |||||||||
| Total Liabilities | $ | 35,742 | $ | 34,650 | |||||||
| Stockholders’ Equity: | |||||||||||
|
Preferred stock, $.0001 par value: authorized 1,000,000 shares; none issued |
- | - | |||||||||
|
Common stock, $.0001 par value: authorized 200,000,000 shares;
issued and outstanding |
2 | 2 | |||||||||
| Additional paid-in capital | 90,020 | 89,783 | |||||||||
| Retained deficit | (44,740 | ) | (47,062 | ) | |||||||
| Total Stockholders’ Equity | 45,282 | 42,723 | |||||||||
| Total Liabilities and Stockholders’ Equity | $ | 81,024 | $ | 77,373 | |||||||
|
INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES |
|||||||||||||||||||||
|
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS |
|||||||||||||||||||||
|
(UNAUDITED) |
|||||||||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||||||||
|
(in thousands, except share and per share data) |
September 30 | September 30 | |||||||||||||||||||
| 2014 | 2013 | 2014 | 2013 | ||||||||||||||||||
| Net revenues: | |||||||||||||||||||||
| Rentals | $ | 14,505 | $ | 14,493 | $ | 44,150 | $ | 41,556 | |||||||||||||
| Product Sales | 2,108 | 1,247 | 6,077 | 3,547 | |||||||||||||||||
| Net revenues | 16,613 | 15,740 | 50,227 | 45,103 | |||||||||||||||||
| Cost of revenues: | |||||||||||||||||||||
| Cost of revenues — Product, service and supply costs | 3,221 | 2,750 | 9,024 | 8,174 | |||||||||||||||||
| Cost of revenues — Pump depreciation and disposals | 1,662 | 1,650 | 5,474 | 4,836 | |||||||||||||||||
| Gross profit | 11,730 | 11,340 | 35,729 | 32,093 | |||||||||||||||||
| Selling, general and administrative expenses: | |||||||||||||||||||||
| Provision for doubtful accounts | 1,266 | 1,795 | 4,811 | 4,782 | |||||||||||||||||
| Amortization of intangibles | 622 | 648 | 1,876 | 1,972 | |||||||||||||||||
| Selling and marketing | 2,483 | 2,391 | 7,762 | 7,281 | |||||||||||||||||
| General and administrative | 4,916 | 4,583 | 14,723 | 14,622 | |||||||||||||||||
| Total selling, general and administrative | 9,287 | 9,417 | 29,172 | 28,657 | |||||||||||||||||
|
Operating income |
2,443 | 1,923 | 6,557 | 3,436 | |||||||||||||||||
| Other income (expense): | |||||||||||||||||||||
| Interest expense | (752 | ) | (838 | ) | (2,355 | ) | (2,636 | ) | |||||||||||||
|
Other income (expense) |
3 | (7 | ) | 26 | 329 | ||||||||||||||||
|
Total other expense |
(749 | ) | (845 | ) | (2,329 | ) | (2,307 | ) | |||||||||||||
| Income before income taxes | 1,694 | 1,078 | 4,228 | 1,129 | |||||||||||||||||
| Income tax expense | (842 | ) | (429 | ) | (1,907 | ) | (324 | ) | |||||||||||||
| Net income | $ | 852 | $ | 649 | $ | 2,321 | $ | 805 | |||||||||||||
| Net income per share: | |||||||||||||||||||||
| Basic | $ | 0.04 | $ | 0.03 | $ | 0.10 | $ | 0.04 | |||||||||||||
| Diluted | $ | 0.04 | $ | 0.03 | $ | 0.10 | $ | 0.04 | |||||||||||||
| Weighted average shares outstanding: | |||||||||||||||||||||
| Basic | 22,203,053 | 21,891,041 | 22,108,143 | 21,851,798 | |||||||||||||||||
| Diluted | 22,511,159 | 22,075,532 | 22,364,999 | 22,043,998 | |||||||||||||||||
| Comprehensive Income | |||||||||||||||||||||
| Net income | $ | 852 | $ | 649 | $ | 2,321 | $ | 805 | |||||||||||||
| Comprehensive income | $ | 852 | $ | 649 | $ | 2,321 | $ | 805 | |||||||||||||
|
INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES |
|||||||||
|
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS |
|||||||||
|
(UNAUDITED) |
|||||||||
| Nine Months Ended | |||||||||
| September 30 | |||||||||
| (in thousands) | 2014 | 2013 | |||||||
| NET CASH PROVIDED BY OPERATING ACTIVITIES | $ | 4,204 | $ | 4,765 | |||||
| INVESTING ACTIVITIES | |||||||||
| Purchase of medical equipment and property | (7,168 | ) | (3,396 | ) | |||||
| Proceeds from sale of medical equipment and property | 5,193 | 2,808 | |||||||
| NET CASH USED IN INVESTING ACTIVITIES | (1,975 | ) | (588 | ) | |||||
| FINANCING ACTIVITIES | |||||||||
| Principal payments on revolving credit facility, term loans and capital lease obligations | (49,101 | ) | (27,912 | ) | |||||
| Cash proceeds from revolving credit facility | 47,814 | 22,395 | |||||||
| Common stock repurchased to satisfy statutory withholding on employee | |||||||||
| stock-based compensation plans | (178 | ) | (78 | ) | |||||
| NET CASH USED IN FINANCING ACTIVITIES | (1,465 | ) | (5,595 | ) | |||||
| Net change in cash and cash equivalents | 764 | (1,418 | ) | ||||||
| Cash and cash equivalents, beginning of period | 1,138 | 2,326 | |||||||
| Cash and cash equivalents, end of period | $ | 1,902 | $ | 908 | |||||
|
INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES |
|||||||||||||||||
|
NON-GAAP RECONCILIATION |
|||||||||||||||||
|
(UNAUDITED) |
|||||||||||||||||
| Three Months Ended | Nine Months Ended | ||||||||||||||||
| September 30, | September 30, | ||||||||||||||||
| (in thousands) | 2014 | 2013 | 2014 | 2013 | |||||||||||||
| Net income | $ | 852 |
|
$ | 649 | $ | 2,321 | $ | 805 | ||||||||
| Adjustments: | |||||||||||||||||
| Interest Expense | 752 | 838 | 2,355 | 2,636 | |||||||||||||
| Income Tax Expense | 842 | 429 | 1,907 | 324 | |||||||||||||
| Depreciation | 938 | 1,365 | 2,595 | 4,010 | |||||||||||||
| Amortization | 622 | 648 | 1,876 | 1,972 | |||||||||||||
| EBITDA | $ | 4,006 | $ | 3,929 | $ | 11,054 | $ | 9,747 | |||||||||
| Stock compensation | 145 | 200 | 417 | 879 | |||||||||||||
| Transition costs | - | - | - | 216 | |||||||||||||
| Strategic Alternatives | - | 126 | - | 429 | |||||||||||||
| EBITDA - Adjusted | $ | 4,151 | $ | 4,255 | $ | 11,471 | $ | 11,271 | |||||||||
Rob Swadosh, 212-922-0900
The Dilenschneider Group
Source: InfuSystem Holdings, Inc.
Released November 10, 2014
